UPDATE: Canaccord Genuity Starts NewLink Genetics (NLNK) at Buy; See Near-Term Catalyst
Tweet
Share
E-mailGet Alerts NLNK Hot Sheet
Price: $0.89 --0%
Rating Summary:
1 Buy, 4 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
1 Buy, 4 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
(Updated - June 1, 2012 8:24 AM EDT)
Canaccord Genuity assumes coverage on NewLink Genetics (NASDAQ: NLNK) with a Buy. PT $23.00.
Analyst, Salveen Richter, said, "The key value driver is HyperAcute Pancreas (HAP) – a novel immunotherapy in P3 clinical trial for surgically-resected pancreatic cancer. A positive P2 (we recognize it was a single-arm study) in addition to the novel cancer vaccine platform are encouraging as we look toward P3 data (first interim analysis in late-2012/early-2013E). We model for peak worldwide HAP sales of $850M in 2020, of which $635M is recognized by NLNK. We view the remainder of the pipeline as a free-call option. While NLNK shares are up ~81% YTD, we believe long-term P2 overall survival data at ASCO (June 4) could serve as a near-term catalyst."
For an analyst ratings summary and ratings history on NewLink Genetics click here. For more ratings news on NewLink Genetics click here.
Shares of NewLink Genetics closed at $12.76 yesterday.
Canaccord Genuity assumes coverage on NewLink Genetics (NASDAQ: NLNK) with a Buy. PT $23.00.
Analyst, Salveen Richter, said, "The key value driver is HyperAcute Pancreas (HAP) – a novel immunotherapy in P3 clinical trial for surgically-resected pancreatic cancer. A positive P2 (we recognize it was a single-arm study) in addition to the novel cancer vaccine platform are encouraging as we look toward P3 data (first interim analysis in late-2012/early-2013E). We model for peak worldwide HAP sales of $850M in 2020, of which $635M is recognized by NLNK. We view the remainder of the pipeline as a free-call option. While NLNK shares are up ~81% YTD, we believe long-term P2 overall survival data at ASCO (June 4) could serve as a near-term catalyst."
For an analyst ratings summary and ratings history on NewLink Genetics click here. For more ratings news on NewLink Genetics click here.
Shares of NewLink Genetics closed at $12.76 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- Jefferies Starts Aehr Test Systems (AEHR) at Buy
- Oppenheimer Starts Carriage Services (CSV) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
